BRCA2 and cancer: Conversely, immunoprecipitation of BRCA2 from EUFA423 B2 (Figure 4C, lanes 1–3) or EUFA423 (Figure 4C, lanes 4–6) cell extracts demonstrates that full-length BRCA2, as well as the cancer-associated BRCA29000insA truncated mutant protein, interact with RNAPII detected by an antibody (601) against its CTD (Nojima et al., 2015).